What is Proteome Sciences plc?
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally.
PMSNF · Verdict
Limited reward · elevated risk
PMSNF's standout is volatility; balance sheet and profitability weigh on the picture.
Based on 88% data coverage
PMSNF · Verdict
Top decile vs peers
Current ratio 0.18
-70% net margin · 0% ROE
Revenue -94.0% CAGR
-21% free-cash-flow margin
Below average
Model-based scoring. For information only — not financial advice.
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 8.77M.
The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.